Pfizer completed its acquisition of Metsera, finalizing a deal that industry sources valued at up to $10 billion. The transaction ends a heated bidding contest with Novo Nordisk and transfers Metsera’s obesity portfolio — including long-acting GLP-1 assets and a fast-acting amylin analog — to Pfizer. The deal accelerates consolidation in obesity therapeutics and gives Pfizer immediate access to late-stage metabolic programs and commercial capabilities. Company statements and regulatory filings indicate the transaction is closed and integration will begin immediately.